Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia
Crossref DOI link: https://doi.org/10.1186/s12962-017-0071-x
Published Online: 2017-05-26
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hatswell, Anthony J.
Thompson, Gwilym J.
Maroudas, Penny A.
Sofrygin, Oleg
Delea, Thomas E.
Funding for this research was provided by:
GlaxoSmithKline